Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2012

01-02-2012 | PRECLINICAL STUDIES

K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)—associated nasopharyngeal carcinoma cells

Authors: Yuen-Keng Ng, Elaine Yue Ling Wong, Cecilia Pik Yuk Lau, Jessica Pui Lan Chan, Sze Chuen Cesar Wong, Andrew Sai-Kit Chan, Maggie Pui Chun Kwan, Sai-Wah Tsao, Chi-Man Tsang, Paul Bo San Lai, Anthony Tak Cheung Chan, Vivian Wai Yan Lui

Published in: Investigational New Drugs | Issue 1/2012

Login to get access

Summary

Recent studies revealed an unexpected role of the neurotrophin receptor pathway, BDNF/TrkB signaling, in cancer metastasis and anoikis (i.e. detachment-induced cell death). Survival of cancer cells in detached state (known as anoikis-resistance) is known to be pre-requisite for metastasis. Nasopharyngeal carcinoma (NPC), an endemic head and neck cancer in Southeast Asia, is highly invasive, metastatic, and etiologically associated with Epstein-Barr virus (EBV, an oncovirus) infection. Mechanistic studies on the invasive/metastatic nature of NPC can facilitate the development of anti-metastatic therapy in NPC. Thus far, the role of BDNF/TrkB signaling in virus-associated human cancer is unclear. Here, using multiple cell line models of NPC with EBV-association (HONE-1-EBV, HK1-LMP1 and C666-1), we investigated the potential involvement of BDNF/TrkB signaling in cellular migration and anoikis-resistant characteristics of NPC. We found that all three EBV-associated NPC cell lines tested were intrinsically anoikis-resistant (i.e. survived in detached state) and expressed both BDNF and TrkB. BDNF stimulation induced cellular migration, but not proliferation of these cells. Further, we examined if pharmacologic targeting of anoikis-resistance of NPC cells can be achievable by a proof-of-concept Trk inhibitor, K252a, in these EBV-associated NPC models. Our results demonstrated that K252a, was able to attenuate BDNF-induced migration and proliferation of NPC cells. More importantly, we demonstrated for the first time that K252a harbored potent anoikis-sensitization activity (i.e. sensitizing cancer cells to detachment-induced cell death) against EBV-associated human cancer cells, namely NPC cells. This proof-of-concept study demonstrated that K252a, a Trk inhibitor, can potentially be used as an anoikis-sensitizing agent in NPC.
Appendix
Available only for authorised users
Literature
1.
Raab-Traub N (2002) Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12(6):431–441PubMedCrossRef
2.
3.
4.
Anderson KE, Mack TM, Silverman DT (2006) Cancer of the pancreas. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York, NY, pp 721–762
5.
Fandi A, Altun M, Azli N et al (1994) Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 21(3):382–397PubMed
6.
Burt RD, Vaughan TL, McKnight B (1992) Descriptive epidemiology and survival analysis of nasopharyngeal carcinoma in the United States. Int J Cancer 52(4):549–556PubMedCrossRef
7.
Yeung WM, Zong YS, Chiu CT et al (1993) Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int J Cancer 53(5):746–750PubMedCrossRef
8.
Dickens P, Srivastava G, Loke SL et al (1992) Epstein-Barr virus DNA in nasopharyngeal carcinomas from Chinese patients in Hong Kong. J Clin Pathol 45(5):396–397PubMedCrossRef
9.
Klein G, Giovanella BC, Lindahl T et al (1974) Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A 71(12):4737–4741PubMedCrossRef
10.
Lui VW, Wong EY, Ho Y et al (2009) STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer 125(8):1884–1893PubMedCrossRef
11.
Chang SH, Chang HC, Hung WC (2008) Transcriptional repression of tissue inhibitor of metalloproteinase-3 by Epstein-Barr virus latent membrane protein 1 enhances invasiveness of nasopharyngeal carcinoma cells. Oral Oncol 44(9):891–897PubMedCrossRef
12.
Tsuji A, Wakisaka N, Kondo S et al (2008) Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma. Clin Cancer Res 14(17):5368–5375PubMedCrossRef
13.
Ho CH, Chen CL, Li WY et al (2009) Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis 30(8):1443–1451PubMedCrossRef
14.
Agulnik M, Epstein JB (2008) Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol 44(7):617–627PubMedCrossRef
15.
Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124(4):619–626PubMedCrossRef
16.
Wang X-C, Wu Y-P, Ye B et al (2009) Suppression of anoikis by SKP2 amplification and overexpression promotes metastasis of esophageal squamous cell carcinoma. Mol Canc Res 7(1):12–22CrossRef
17.
Zhang X, Su L, Pirani A et al (2006) Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis 23(3):209PubMedCrossRef
18.
Duxbury MS, Ito H, Zinner MJ et al (2004) Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 135(5):555PubMedCrossRef
19.
Duxbury MS, Ito H, Zinner MJ, et al. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 23(2):465
20.
Swan EA, Jasser SA, Holsinger FC et al (2003) Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol 39(7):648PubMedCrossRef
21.
Zhu Z, Sanchez-Sweatman O, Huang X et al (2001) Anoikis and metastatic potential of cloudman S91 melanoma cells. Cancer Res 61(4):1707–1716PubMed
22.
Geiger TR, Peeper DS (2007) Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res 67(13):6221–6229PubMedCrossRef
23.
Geiger TR, Peeper DS (2005) The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective. Cancer Res 65(16):7033–7036PubMedCrossRef
24.
Douma S, Van Laar T, Zevenhoven J et al (2004) Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430(7003):1034–1039PubMedCrossRef
25.
Zhang Z, Han L, Liu Y et al. (2008) Up-regulation of tropomyosin related kinase B contributes to resistance to detachment-induced apoptosis in hepatoma multicellular aggregations. Mol Biol Rep
26.
Zhang Z, Cao L, Li J et al (2008) Acquisition of anoikis resistance reveals a synoikis-like survival style in BEL7402 hepatoma cells. Cancer Lett 267(1):106–115PubMedCrossRef
27.
Yu X, Liu L, Cai B et al (2008) Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Science 99(3):543–552PubMedCrossRef
28.
Sclabas GM, Fujioka S, Schmidt C et al (2005) Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 11(2):440–449PubMed
29.
Martin-Zanca D, Hughes SH, Barbacid M (1986) A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 319(6056):743–748PubMedCrossRef
30.
Katzav S, Martin-Zanca D, Barbacid M et al (1989) The trk oncogene abrogates growth factor requirements and transforms hematopoietic cells. Oncogene 4(9):1129–1135PubMed
31.
Mawji IA, Simpson CD, Gronda M et al (2007) A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res 67(17):8307–8315PubMedCrossRef
32.
Evans AE, Kisselbach KD, Yamashiro DJ et al (1999) Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 5(11):3594–3602PubMed
33.
Wang Y, Hagel C, Hamel W et al (1998) Trk A, B, and C are commonly expressed in human astrocytes and astrocytic gliomas but not by human oligodendrocytes and oligodendroglioma. Acta Neuropathol 96(4):357–364PubMedCrossRef
34.
Wadhwa S, Nag TC, Jindal A et al (2003) Expression of the neurotrophin receptors Trk A and Trk B in adult human astrocytoma and glioblastoma. J Biosci 28(2):181–188PubMedCrossRef
35.
Yang ZF, Ho DW, Lam CT et al (2005) Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. Cancer Res 65(1):219–225PubMed
36.
Kupferman ME, Jiffar T, El-Naggar A et al (2010) TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 29(14):2047–2059PubMedCrossRef
37.
Zhao W, Wen W, Zhang Z et al (2007) Expression and significance of tyrosine kinase receptors B in nasopharyngeal carcinoma patients. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 21(11):497–500PubMed
38.
Anderson RA, Robinson LL, Brooks J et al (2002) Neurotropins and their receptors are expressed in the human fetal ovary. J Clin Endocrinol Metab 87(2):890–897PubMedCrossRef
39.
Hong B, Lui VW, Hui EP et al. (2009) Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activation. Invest New Drugs
40.
Lui VW, Boehm AL, Koppikar P et al (2007) Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol 71(5):1435–1443PubMedCrossRef
41.
Lui VW, Thomas SM, Zhang Q et al (2003) Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 22(40):6183–6193PubMedCrossRef
42.
Lui VW, Yau DM, Wong EY et al (2009) Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 30(12):2085–2094PubMedCrossRef
43.
Diaz-Montero CM, Wygant JN, McIntyre BW (2006) PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation. Eur J Cancer 42(10):1491–1500PubMedCrossRef
44.
Akinaga S, Ashizawa T, Gomi K et al (1992) Antitumor effect of KT6124, a novel derivative of protein kinase inhibitor K-252a, and its mechanism of action. Cancer Chemother Pharmacol 29(4):266–272PubMedCrossRef
45.
Festuccia C, Gravina GL, Muzi P et al (2007) In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma. Prostate 67(12):1255–1264PubMedCrossRef
46.
Perez-Pinera P, Hernandez T, Garcia-Suarez O et al (2007) The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas. Mol Cell Biochem 295(1–2):19–26PubMedCrossRef
47.
Miknyoczki SJ, Chang H, Klein-Szanto A et al (1999) The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin Cancer Res 5(8):2205–2212PubMed
48.
Miknyoczki SJ, Dionne CA, Klein-Szanto AJ et al (1999) The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann N Y Acad Sci 880:252–262PubMedCrossRef
49.
Morotti A, Mila S, Accornero P et al (2002) K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21(32):4885–4893PubMedCrossRef
50.
Takai N, Ueda T, Nishida M et al (2005) K252a inhibits proliferation of ovarian cancer cells by upregulating p21WAF1. Oncol Rep 14(1):141–143PubMed
51.
Takai N, Ueda T, Nishida M et al (2008) K252a is highly effective in suppressing the growth of human endometrial cancer cells, but has little effect on normal human endometrial epithelial cells. Oncol Rep 19(3):749–753PubMed
52.
Marshall JL, Kindler H, Deeken J et al (2005) Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 23(1):31–37PubMedCrossRef
53.
Undevia SD, Vogelzang NJ, Mauer AM et al (2004) Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs 22(4):449–458PubMedCrossRef
54.
Strock CJ, Park JI, Rosen M et al (2003) CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res 63(17):5559–5563PubMed
55.
Smith BD, Levis M, Beran M et al (2004) Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 103(10):3669–3676PubMedCrossRef
56.
Thress K, Macintyre T, Wang H et al (2009) Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther 8(7):1818–1827PubMedCrossRef
57.
Cazorla M, Jouvenceau A, Rose C et al (2010) Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS One 5(3):e9777PubMedCrossRef
Metadata
Title
K252a induces anoikis-sensitization with suppression of cellular migration in Epstein-Barr Virus (EBV)—associated nasopharyngeal carcinoma cells
Authors
Yuen-Keng Ng
Elaine Yue Ling Wong
Cecilia Pik Yuk Lau
Jessica Pui Lan Chan
Sze Chuen Cesar Wong
Andrew Sai-Kit Chan
Maggie Pui Chun Kwan
Sai-Wah Tsao
Chi-Man Tsang
Paul Bo San Lai
Anthony Tak Cheung Chan
Vivian Wai Yan Lui
Publication date
01-02-2012
Publisher
Springer US
Published in
Investigational New Drugs / Issue 1/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-010-9513-4

Other articles of this Issue 1/2012

Investigational New Drugs 1/2012 Go to the issue

PHASE I STUDIES

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers

PHASE I STUDIES

Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies

PHASE I STUDIES

Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer

PHASE II STUDIES

Combined treatment with Bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients

PRECLINICAL STUDIES

Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression

PRECLINICAL STUDIES

Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits